Drug Trial Radar · NCT05990543
Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
59
Planned (sponsor's estimate)
Start
Jan 29, 2024
Primary completion
Dec 1, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Korea University Anam HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label clinical trial aimed at evaluating the safety and efficacy of the combination treatment of nelmastobart with capecitabine in patients diagnosed with metastatic or recurrent colorectal cancer.
Conditions
- Recurrent or Metastatic Colorectal Cancer
Interventions
Nelmastobart and CapecitabineDrug
Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle. Capecitabine is administered orally for two weeks followed by a one-week rest period
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated DoseTime frame: Up to approximately 2 years
- Progression free survivalTime frame: Up to approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Medical Center 73, Goryeodae-ro, Seongbuk-gu
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.